Cell line · CVCL_1508
Papers37
1 to 20 of 37
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Activation of polyamine catabolism promotes glutamine metabolism and creates a targetable vulnerability in lung cancer. | Proc Natl Acad Sci U S A | 2024 | Its Methods give the RRID and name the line | PubMed | |
| TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity. | Cancer Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer. | EBioMedicine | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Sperm-specific COX6B2 enhances oxidative phosphorylation, proliferation, and survival in human lung adenocarcinoma. | Elife | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. | Elife | 2020 | Its Methods give the RRID and name the line | PubMed | |
| A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. | Cancer Cell | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. | Cell Chem Biol | 2020 | Its Methods give the RRID and name the line | PubMed | |
| From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. | J Cell Biochem | 2020 | Cellosaurus cites it | PubMed | |
| Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer. | Elife | 2019 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1508/papers